Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Heart Failure
100%
Patients with Heart Failure
100%
Reduced Ejection Fraction
100%
Dapagliflozin
100%
Hazard Ratio
50%
Heart Failure Hospitalization
50%
Risk of Death
37%
Risk Measures
37%
Cardiovascular Mortality
25%
Worsening Heart Failure
25%
Intravenous Therapy
25%
Placebo Groups
12%
Composite Outcome
12%
Non-fatal
12%
First Episode
12%
Mortality Risk
12%
Left Ventricular Ejection Fraction
12%
Prognostic Importance
12%
Oral Treatment
12%
Adverse Outcomes
12%
Oral Therapy
12%
Heart Failure Symptoms
12%
New York Heart Association Functional Class
12%
Unique Identifier
12%
Heart Failure Trials
12%
Patient numbers
12%
N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)
12%
Guideline-directed Medical Therapy
12%
Medicine and Dentistry
Outpatient
100%
Ejection Fraction
100%
Congestive Heart Failure
100%
Dapagliflozin
100%
Hazard Ratio
25%
Intravenous Drug Administration
12%
Oral
12%
Cardiovascular System
12%
Placebo
6%
Amino Terminal Sequence
6%
Brain Natriuretic Peptide
6%
Heart Left Ventricle Ejection Fraction
6%
Adverse Outcome
6%
New York Heart Association Class
6%
Median Follow Up
6%
Nursing and Health Professions
Outpatient
100%
Congestive Heart Failure
100%
Heart Ejection Fraction
100%
Dapagliflozin
100%
Hazard Ratio
25%
Intravenous Drug Administration
12%
Cardiovascular System
12%
Placebo
6%
Practice Guideline
6%
New York Heart Association Class
6%
Adverse Outcome
6%
Heart Left Ventricle Ejection Fraction
6%
Brain Natriuretic Peptide
6%
Immunology and Microbiology
Heart Ejection Fraction
100%
Cardiovascular System
100%
Amino Terminal Sequence
50%
Heart Left Ventricle Ejection Fraction
50%
Natriuretic Peptide
50%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Dapagliflozin
100%
Intravenous Therapy
12%
Placebo
6%
Brain Natriuretic Peptide
6%
Adverse Outcome
6%